SEQUENT SCIENTIFIC Financial Statement Analysis
|
||
|
The Revenues of SEQUENT SCIENTIFIC have increased by 13.26% YoY .
The Earnings Per Share (EPS) of SEQUENT SCIENTIFIC has increased by Positive YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SEQUENT SCIENTIFIC Last 5 Annual Financial Results
[BOM: 512529|NSE : SEQUENT]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹1,551 Cr | ₹1,370 Cr | ₹1,421 Cr | ₹1,413 Cr | ₹1,362 Cr |
| Expenses | ₹1,393 Cr | ₹1,308 Cr | ₹1,409 Cr | ₹1,303 Cr | ₹1,152 Cr |
| Operating Profit (Excl OI) | ₹159 Cr | ₹61 Cr | ₹12 Cr | ₹109 Cr | ₹210 Cr |
| Other Income | ₹18 Cr | ₹11 Cr | ₹6.39 Cr | ₹11 Cr | ₹10 Cr |
| Interest | ₹61 Cr | ₹48 Cr | ₹36 Cr | ₹16 Cr | ₹24 Cr |
| Depreciation | ₹66 Cr | ₹62 Cr | ₹56 Cr | ₹52 Cr | ₹51 Cr |
| Profit Before Tax | ₹44 Cr | ₹-55 Cr | ₹-138 Cr | ₹53 Cr | ₹137 Cr |
| Profit After Tax | ₹32 Cr | ₹-30 Cr | ₹-122 Cr | ₹45 Cr | ₹104 Cr |
| Consolidated Net Profit | ₹22 Cr | ₹-36 Cr | ₹-121 Cr | ₹41 Cr | ₹95 Cr |
| Earnings Per Share (Rs) | ₹0.87 | ₹-1.44 | ₹-4.86 | ₹1.65 | ₹3.84 |
| PAT Margin (%) | 2.02 | -2.10 | -8.39 | 3.10 | 7.53 |
| ROE(%) | 5.44 | -4.85 | -18.95 | 6.56 | 15.00 |
| ROCE(%) | 9.30 | -0.60 | -9.71 | 7.01 | 16.24 |
| Total Debt/Equity(x) | 0.73 | 0.78 | 0.62 | 0.49 | 0.31 |
Key Financials |
||
| Market Cap | : | ₹ 6,371.8 Cr |
| Revenue (TTM) | : | ₹ 1,657.9 Cr |
| Net Profit(TTM) | : | ₹ 54.0 Cr |
| EPS (TTM) | : | ₹ 2.1 |
| P/E (TTM) | : | 117.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SEQUENT SCIENTIFIC | 10.1% | 24.1% | 27.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.8% | 6.3% | -1.1% |
| DIVIS LABORATORIES | -2.1% | -2.5% | 12.2% |
| CIPLA | 0% | -3.3% | 0.6% |
| TORRENT PHARMACEUTICALS | -2.5% | 4.2% | 21.5% |
| DR REDDYS LABORATORIES | 1.3% | -0.5% | -0.2% |
| MANKIND PHARMA | -1.5% | -10.3% | -12.1% |
| ZYDUS LIFESCIENCES | -1.5% | -5.8% | -3.7% |
| LUPIN | -1.4% | 4.5% | 0.4% |
SEQUENT SCIENTIFIC Revenues
[BOM: 512529|NSE : SEQUENT]
| Y-o-Y | 13.26 % |
| 5 Yr CAGR | 3.32 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,551 Cr | 13.26 | |
| Mar2024 | ₹1,370 Cr | -3.60 | |
| Mar2023 | ₹1,421 Cr | 0.57 | |
| Mar2022 | ₹1,413 Cr | 3.76 | |
| Mar2021 | ₹1,362 Cr | - | |
SEQUENT SCIENTIFIC Operating Profit
[BOM: 512529|NSE : SEQUENT]
| Y-o-Y | 158.68 % |
| 5 Yr CAGR | -6.73 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹159 Cr | 158.68 | |
| Mar2024 | ₹61 Cr | 413.71 | |
| Mar2023 | ₹12 Cr | -89.07 | |
| Mar2022 | ₹109 Cr | -47.90 | |
| Mar2021 | ₹210 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 128.57 % |
| 5 Yr CAGR | -9.73 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 10.24% | 128.57 | |
| Mar2024 | 4.48% | 433.33 | |
| Mar2023 | 0.84% | -89.15 | |
| Mar2022 | 7.74% | -49.81 | |
| Mar2021 | 15.42% | - | |
SEQUENT SCIENTIFIC Profit After Tax
[BOM: 512529|NSE : SEQUENT]
| Y-o-Y | Positive |
| 5 Yr CAGR | -30.81 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹22 Cr | Positive | |
| Mar2024 | ₹-36 Cr | Negative | |
| Mar2023 | ₹-121 Cr | Negative | |
| Mar2022 | ₹41 Cr | -57.09 | |
| Mar2021 | ₹95 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | -28.03 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 2.02 % | Positive | |
| Mar2024 | -2.1 % | Negative | |
| Mar2023 | -8.39 % | Negative | |
| Mar2022 | 3.1 % | -58.83 | |
| Mar2021 | 7.53 % | - | |
SEQUENT SCIENTIFIC Earnings Per Share (EPS)
[BOM: 512529|NSE : SEQUENT]
| Y-o-Y | Positive |
| 5 Yr CAGR | -31.01 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.87 | Positive | |
| Mar2024 | ₹-1.44 | Negative | |
| Mar2023 | ₹-4.86 | Negative | |
| Mar2022 | ₹1.65 | -57.03 | |
| Mar2021 | ₹3.84 | - | |
SEQUENT SCIENTIFIC Return on Capital Employed (ROCE)
[BOM: 512529|NSE : SEQUENT]
| Y-o-Y | Positive |
| 5 Yr CAGR | -13.01 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 9.3% | Positive | |
| Mar2024 | -0.6% | Negative | |
| Mar2023 | -9.71% | Negative | |
| Mar2022 | 7.01% | -56.83 | |
| Mar2021 | 16.24% | - | |
SEQUENT SCIENTIFIC Share Price vs Sensex
| Current Share Price | : | ₹252.0 |
| Current MarketCap | : | ₹ 6,371.8 Cr |
| Updated EOD on | : | Nov 19,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SEQUENT SCIENTIFIC | 10.1% |
24.1% |
27.1% |
| SENSEX | 0.9% |
2.1% |
8.3% |
SEQUENT SCIENTIFIC related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | 0.2% | -0.1% | 3.4% |
| BSE SMALLCAP | -0.9% | -1% | -1.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | 0.3% | 1.4% | 6.7% |
| NIFTY MICROCAP 250 | -0.6% | -0% | -2.7% |
| NIFTY MIDSMALL HEALTHCARE | -0.8% | -0.9% | 5.2% |
You may also like the below Video Courses
FAQ about SEQUENT SCIENTIFIC Financials
How the annual revenues of SEQUENT SCIENTIFIC have changed ?
The Revenues of SEQUENT SCIENTIFIC have increased by 13.26% YoY .
How the Earnings per Share (EPS) of SEQUENT SCIENTIFIC have changed?
The Earnings Per Share (EPS) of SEQUENT SCIENTIFIC has increased by Positive YoY .
Check out Intrinsic Value of Peers of SEQUENT SCIENTIFIC
Compare Stock Analytics of Peers of SEQUENT SCIENTIFIC
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
